Advancing a New Therapeutic Approach for Mesothelioma Through Collaboration
Vector Bioscience Cambridge has established a new collaboration with researchers from the University of Glasgow to develop and
July 11, 2025
The most versatile targeted delivery
Deploying breakthrough research from Cambridge to tangible applications
Vector's Science
Vector Bioscience develops a machine-learning empowered drug delivery platform. We are dedicated to transforming oncology treatments with our cargo-agnostic technology. Our precision-targeted delivery minimizes side effects with a higher uptake and slow release. By tailoring delivery, we achieve high local concentrations of traditionally difficult-to-formulate therapeutics.
How our technology works
Data
Data-driven selection of cargoes & customisation for specific cancers
Dry Lab
ML-enabled material selection
Wet Lab
Engineering of cargo and drug loading
Novel Medical Treatment
Personalized & precision medicines
Data
Data-driven selection of cargoes & antibodies for specific cancers
Dry Lab
ML-enabled material selection
Wet Lab
Engineering of cargo and drug loading
.
Personalized & precision medicines
About our Nanoshutle technology
Play Video
Statistics
What we’ve done so far
0
2022
From
0
3
Patents filed
$ 0
M+
non-dilutive funding
LAB 0
State—Of—The—Art Facilities
0
y+
R&D development
0
team Members
the people behind Vector
Vector Team
Advisory Board
Biology & IP
Oncology & Clinical Trials
Formulation
Modalities
Our Culture
We believe in pushing boundaries, prioritising excellence. We have the top experts, specialists, scientists (and data!) are part of our team. Together, we work to progress Vector’s nanoparticle shuttle to the clinic. Our technology pioneers the future oncology treatment and our drive is to bring it to patients, improving treatments and their quality of life.
Vision
We are providing the ultimate precision medicine, enacting a paradigm change in drug therapy development. Through pioneering tomorrow’s therapies we are building a future where we do not fear cancer.
Mission
We want to improve treatments for patients maximising efficacy and minimising side-effects and bringing the 3 Ls to life:
Low side-effects
Localised delivery – directly to where treatment is needed
Loading – greater uptake of drugs
Pipeline
We’re committed to delivering novel treatments to rare disease patients
ML identification
Formulation & delivery
In vitro studies
In vivo studies
Clinical planning
Partner confirmation
Pancreatic cancer 01
Pancreatic cancer 02
Lung cancer
Glioblastoma
Colorectal cancer
Prostate cancer
Breast cancer
What’s New In The Field And Our Labs
Vector Bioscience Cambridge joins the Milner Therapeutics Institute Affiliate Scheme
We are pleased to announce that Vector Bioscience Cambridge has joined the Milner Therapeutics Institute as an Affiliated
July 9, 2025
Vector Bioscience Cambridge Joins EU4MOFs COST Action Network
We are pleased to announce that Vector Bioscience Cambridge has joined the EU4MOFs COST Action network, a European
May 28, 2025
Some of our partners and collaborators
Get in touch to explore opportunities. Partner with us
Address
Vector Bioscience Cambridge
The Hauser Forum
3, Charles Babbage Rd
CB3 0GT Cambridge
United Kingdom
Mail Address
contact@vectorbiocam.com